Treats Parkinson's disease. Sold as Neupro. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Rotigotine (sold as Neupro), first approved May 9, 2007, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Neupro | Part D | $81.2M | -10% | 13,419 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Adhesion and Safety of Rotigexole Compared to Neupro®Idiopathic Parkinson Disease · Eva Pharma | Not applicable | Not yet recruiting | Jun 11, 2025 |
| A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's DiseaseAlzheimer Disease · I.R.C.C.S. Fondazione Santa Lucia | Phase 3 | Recruiting | Nov 22, 2024 |
| Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney DiseaseKidney Diseases · University Hospital, Rouen | Phase 2 | Recruiting | Mar 4, 2024 |
| Quality Improvement and Practice Based Research in Neurology Using the EMRBrain Tumors, Epilepsy · Endeavor Health | Phase 4 | Enrolling by invitation | Feb 1, 2016 |
| Infusion of Apomorphine: Long-term Safety StudyIdiopathic Parkinson's Disease · MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Phase 3 | Active, not recruiting | Jan 15, 2015 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
